Fisetin for Aging
Fisetin is a leading senolytic candidate that extends healthspan in aged mice, but there is no rigorous human evidence that it slows aging, reduces frailty, or extends lifespan. Until controlled trials report, it should be considered experimental rather than a proven anti-aging supplement.
Why this grade7-layer evidence engine
The grade is Weak (Tier C) because the strongest data are preclinical. In aged mice, fisetin was the most potent senolytic of ten flavonoids screened and extended healthspan and lifespan (PMID 30279143), and a 2025 study showed intermittent dosing improved physical function and lowered muscle senescence, rivaling genetic clearance of senescent cells (PMID 40437670). Mechanistically this is plausible, but animal results do not establish human benefit.
Human evidence is thin and unconvincing. The only published trials are tiny, open-label pilots without placebo controls: one (n=10) found biological age dropped in just 4 of 10 people, rose in 5, and left telomere length unchanged, with no significant effect and authors advising against use pending larger studies (PMID 39269340). An industry-funded study (n=19) found a dasatinib-quercetin-fisetin regimen produced only non-significant changes in epigenetic clocks (PMID 38393697). No double-blind anti-aging RCT has reported results.
Regulators and clinicians reinforce the caution. The US FDA has issued warning letters over fisetin disease claims, and Health Canada licenses it only for an antioxidant claim, not anti-aging or senolytic effects. Mayo Clinic researchers explicitly warn against using commercial fisetin as an anti-aging agent without knowing the right dose, and major geroscience societies state there are currently no proven anti-aging supplements. It also carries theoretical drug-interaction concerns, including with blood thinners.
Scoring transparency
All scores computed by a 7-layer evidence engine — fully auditable▸View the full decision path (audit trail)
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.445
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 無高階證據可裁決
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 1 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status